Skip to content
Menu

Barclays Maintains Equal-Weight on Minimed Group, Lowers Price Target to $20

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Christopher Pasquale maintains Minimed Group (NASDAQ:MMED) with a Equal-Weight and lowers the price target from $22 to $20.

Barclays analyst Christopher Pasquale maintains Minimed Group (NASDAQ:MMED) with a Equal-Weight and lowers the price target from $22 to $20.

Read at benzinga.com